The Ultimate Metabolic Stack: Semaglutide, AOD-9604, 5-Amino-1MQ & Tesamorelin

Body recomposition — simultaneously reducing fat mass and preserving or gaining lean mass — requires intervention across multiple metabolic pathways. This stack combines Semaglutide (or Tirzepatide) for appetite regulation and insulin sensitization, AOD-9604 for targeted lipolysis, 5-Amino-1MQ for NAD+-driven fat cell metabolism, and Tesamorelin for GHRH-mediated visceral fat reduction.

Stack Overview

Individual Peptide Roles

Semaglutide: The Appetite Regulator

Semaglutide is a modified GLP-1 (glucagon-like peptide-1) analog with 94% homology to native GLP-1 but an albumin-binding fatty acid chain that extends its half-life to approximately 7 days, enabling once-weekly dosing.

• Central appetite suppression — Semaglutide crosses the blood-brain barrier and activates GLP-1 receptors in the hypothalamus (arcuate nucleus) and brainstem (area postrema, nucleus tractus solitarius), reducing hunger and food reward signaling Blundell et al., 2017
• Gastric emptying delay — Slows gastric motility, prolonging satiety after meals and reducing postprandial glucose spikes
• Beta-cell preservation — Protects and promotes pancreatic beta-cell survival, improving insulin secretion capacity over time Drucker, 2018
• Weight loss efficacy — The STEP 1 trial demonstrated 14.9% mean body weight reduction over 68 weeks at 2.4 mg/week Wilding et al., 2021
• Cardiovascular benefit — The SELECT trial showed a 20% reduction in major adverse cardiovascular events (MACE) in overweight/obese individuals without diabetes Lincoff et al., 2023

Tirzepatide as Alternative

Tirzepatide is a dual GIP/GLP-1 receptor agonist that may offer superior weight loss and glucose control compared to semaglutide alone. The SURMOUNT-1 trial showed up to 22.5% body weight reduction at the highest dose (15 mg/week) Jastreboff et al., 2022.

AOD-9604: The Lipolysis Specialist

AOD-9604 is a modified 16-amino acid fragment of human growth hormone (amino acids 176-191), with an additional tyrosine at the N-terminus. It retains the fat-reducing properties of GH without its growth-promoting or diabetogenic effects.

• Lipolysis stimulation — Activates lipolysis through the beta-3 adrenergic receptor pathway, mobilizing stored triglycerides from adipocytes Heffernan et al., 2001
• Lipogenesis inhibition — Simultaneously inhibits the formation of new fat, creating a dual anti-adiposity effect
• No IGF-1 elevation — Unlike full-length GH or GHRH analogs, AOD-9604 does not increase IGF-1 levels, avoiding the growth-promoting and potentially diabetogenic effects of GH Ng et al., 2000
• No glucose disruption — Does not impair glucose tolerance or insulin sensitivity, making it safe to combine with GLP-1 agonists that improve glucose metabolism
• Cartilage repair — AOD-9604 (as licensed under the name "OsteoGraf") has also shown beneficial effects on cartilage regeneration, an added benefit for individuals undergoing body recomposition with increased physical activity Kwon et al., 2012

5-Amino-1MQ: The Fat Cell Reprogrammer

5-Amino-1MQ targets the enzyme nicotinamide N-methyltransferase (NNMT), which is overexpressed in adipose tissue of obese individuals and plays a key role in fat cell metabolism.

• NNMT inhibition — NNMT methylates nicotinamide (vitamin B3), diverting it from the NAD+ salvage pathway. In obesity, NNMT is upregulated in white adipose tissue, creating a metabolic "sink" that depletes NAD+ and impairs cellular energy metabolism Kraus et al., 2014
• NAD+ restoration — By blocking NNMT, 5-Amino-1MQ restores NAD+ levels, supporting sirtuin-mediated metabolic regulation and mitochondrial function in adipocytes
• Adipocyte reprogramming — Treated adipocytes show reduced lipid accumulation, decreased expression of adipogenic genes, and increased oxygen consumption (a marker of metabolic activity) Neelakantan et al., 2017
• SAM cycle effects — NNMT consumes S-adenosylmethionine (SAM) as a methyl donor. Inhibiting NNMT increases SAM availability, which has broad effects on methylation reactions throughout the body
• Oral bioavailability — Unlike most peptides, 5-Amino-1MQ is a small molecule with oral bioavailability, eliminating the need for injection

Tesamorelin: The Visceral Fat Reducer

Tesamorelin is a synthetic GHRH analog (growth hormone-releasing hormone with a trans-3-hexenoic acid modification) that is FDA-approved for the treatment of HIV-associated lipodystrophy — excess visceral adipose tissue accumulation.

• Pulsatile GH release — Stimulates the anterior pituitary to release GH in a physiological pulsatile pattern, avoiding the flat supraphysiological profile of exogenous GH injection Falutz et al., 2007
• Visceral fat specificity — Clinical trials demonstrated an 18% reduction in visceral adipose tissue (VAT) over 26 weeks. Visceral fat is the most metabolically dangerous fat depot, strongly associated with cardiovascular disease, insulin resistance, and systemic inflammation Falutz et al., 2007
• Trunk fat reduction — Reduces trunk fat without significant effects on extremity subcutaneous fat, specifically targeting the abdominal compartment
• IGF-1 elevation — Raises IGF-1 levels, which contributes to lean mass preservation and fat oxidation. However, this differentiates it from AOD-9604 and requires monitoring
• Liver fat reduction — Reduced hepatic fat content in patients with HIV-associated lipodystrophy and nonalcoholic fatty liver disease Stanley et al., 2014

Mechanism of Synergy

Each peptide in this stack addresses a different layer of metabolic dysfunction:

Layer 1 — Caloric Intake (Semaglutide): Reduces appetite through central GLP-1R activation, creating the caloric deficit necessary for fat loss. Improves insulin sensitivity and glucose handling, shifting the metabolic environment toward fat oxidation.

Layer 2 — Fat Mobilization (AOD-9604): Directly stimulates lipolysis in adipose tissue, mobilizing stored triglycerides for energy use. Blocks new fat formation. Works independently of the GH/IGF-1 axis, avoiding diabetogenic effects.

Layer 3 — Fat Cell Metabolism (5-Amino-1MQ): Reprograms adipocyte metabolism at the enzymatic level, restoring NAD+ availability and increasing cellular energy expenditure. Addresses the root cause of metabolic dysfunction in obese adipose tissue.

Layer 4 — Visceral Fat & Body Composition (Tesamorelin): Specifically targets visceral fat through pulsatile GH release. Preserves lean mass through IGF-1 elevation. Reduces hepatic fat content.

The result is a comprehensive approach that reduces caloric intake, mobilizes existing fat stores, reprograms fat cell metabolism, and specifically targets the most dangerous visceral fat depot.

Research Protocol

Dosing Table

Semaglutide Titration Schedule

Titration is essential. Starting at high doses causes significant nausea, vomiting, and GI distress. The slow escalation allows GI tolerance to develop.

Timing & Meal Considerations

• Fasting windows — AOD-9604 and Tesamorelin both perform optimally in a fasted state. If practicing intermittent fasting, administer both during the fasting window
• Exercise timing — Administer AOD-9604 before morning exercise for maximum lipolytic synergy with exercise-induced catecholamine release
• Semaglutide injection day — Choose a consistent day each week. Some individuals experience transient nausea on injection day; scheduling it on a less demanding day can be practical

Cycling Recommendations

• Semaglutide discontinuation — The most significant challenge in this stack. Weight regain after semaglutide cessation is well-documented (approximately two-thirds of weight loss regained within 1 year of stopping). Tapering and maintaining lifestyle changes is critical Wilding et al., 2022
• Staggered cycling — Consider maintaining semaglutide continuously while cycling the other three components in and out to provide ongoing appetite support

Blood Work & Monitoring

Baseline (Before Starting)

Monthly Monitoring (During Protocol)

• Weight and waist circumference — Weekly tracking
• Fasting glucose — Monthly; watch for divergent effects (semaglutide lowers, Tesamorelin's GH effect may raise)
• GI symptom assessment — Nausea, constipation, and diarrhea frequency and severity (semaglutide-related)
• IGF-1 — Every 4-8 weeks while on Tesamorelin. Target physiological range; excessive elevation warrants dose reduction

Mid-Protocol (Week 12)

• Full lipid panel — expect triglyceride reduction and HDL improvement
• HbA1c recheck
• Liver panel — monitor for Tesamorelin's hepatic fat reduction effect
• Repeat DEXA scan to quantify body composition changes
• Amylase and lipase — ongoing pancreatic safety monitoring

Post-Protocol (4 Weeks After Cessation)

• Full panel repeat
• DEXA scan to assess fat redistribution after cessation
• IGF-1 to confirm return to baseline (Tesamorelin)

Safety Considerations

• Semaglutide GI effects — Nausea (44% in STEP 1), vomiting, diarrhea, and constipation are the most common side effects. These are dose-dependent and typically improve with time and proper titration. Rare but serious: pancreatitis (monitor amylase/lipase), gallbladder disease, and a theoretical thyroid C-cell tumor risk based on rodent studies (monitored by calcitonin levels) Wilding et al., 2021
• Muscle loss — GLP-1 agonist-induced weight loss includes significant lean mass loss (up to 40% of total weight lost can be lean mass). Adequate protein intake (1.2-1.6 g/kg/day) and resistance training are essential countermeasures. Tesamorelin's GH-mediated IGF-1 elevation may partially offset this effect
• AOD-9604 — Generally well-tolerated in clinical studies. No significant effects on glucose or IGF-1. Injection site reactions are the primary adverse effect. Received GRAS (Generally Recognized As Safe) status from the FDA for oral food supplement use
• 5-Amino-1MQ — Limited human safety data. NNMT inhibition affects methylation pathways broadly. Monitor liver function. Theoretical concerns about long-term epigenetic effects. Avoid in pregnancy
• Tesamorelin — FDA-approved with well-characterized safety profile. Common side effects: injection site reactions, joint pain, peripheral edema. Contraindicated in active malignancy (GH/IGF-1 elevation), pregnancy, and pituitary pathology. May impair glucose tolerance through GH-mediated insulin resistance — monitor fasting glucose Falutz et al., 2007
• Glucose cross-effects — Semaglutide improves glucose tolerance while Tesamorelin's GH effect may worsen it. In most cases, semaglutide's glucose-lowering effect predominates, but close glucose monitoring is warranted, especially in pre-diabetic individuals

Important: Adequate protein intake and resistance training are non-negotiable components of any metabolic stack protocol. GLP-1 agonist-induced weight loss without these countermeasures leads to excessive muscle loss, which worsens metabolic rate and body composition long-term.

References

1. Blundell et al., 2017 — Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight
2. Drucker, 2018 — Mechanisms of action and therapeutic application of glucagon-like peptide-1
3. Wilding et al., 2021 — Once-weekly semaglutide in adults with overweight or obesity (STEP 1)
4. Lincoff et al., 2023 — Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)
5. Jastreboff et al., 2022 — Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)
6. Heffernan et al., 2001 — The effects of hGH fragment AOD-9604 on body fat in obese mice
7. Ng et al., 2000 — Metabolic effects of human growth hormone fragment 176-191
8. Kwon et al., 2012 — AOD-9604 effects on cartilage regeneration
9. Kraus et al., 2014 — NNMT knockdown in adipose tissue promotes browning and protection from diet-induced obesity
10. Neelakantan et al., 2017 — Structure-activity relationship for small molecule inhibitors of nicotinamide N-methyltransferase
11. Falutz et al., 2007 — Metabolic effects of a growth hormone-releasing factor in patients with HIV lipodystrophy
12. Stanley et al., 2014 — Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation
13. Wilding et al., 2022 — Weight regain and cardiometabolic effects after withdrawal of semaglutide